This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via ISI Web of Science (32)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rasmussen, S. A.
Right arrow Articles by Friedman, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rasmussen, S. A.
Right arrow Articles by Friedman, J. M.
Related Collections
Right arrow Genetics & Dysmorphology

PEDIATRICS Vol. 111 No. 4 April 2003, pp. 777-784

Population-Based Analyses of Mortality in Trisomy 13 and Trisomy 18

Sonja A. Rasmussen, MD, MS*, Lee-Yang C. Wong, MS{ddagger}, Quanhe Yang, PhD*, Kristin M. May, PhD§ and J. M. Friedman, MD, PhD||

* National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia
{ddagger} Health Investigations Branch, Division of Health Studies, Agency for Toxic Substances and Disease Registry, Atlanta, Georgia
§ Department of Pediatrics, Division of Medical Genetics, Emory University School of Medicine, Atlanta, Georgia
|| Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada

--> Objective. Although trisomy 13 and trisomy 18 are generally considered to be lethal, long-term survival of patients has been reported. We sought to evaluate mortality in people with trisomy 13 or 18 using 2 population-based strategies.

Methods. In the first analysis, infants who had trisomy 13 or 18 and were born during 1968–1999 were identified using the Metropolitan Atlanta Congenital Defects Program, a population-based birth defects surveillance system. Dates of death were documented using hospital records, Georgia vital records, and the National Death Index. In the second analysis, we used the Multiple-Cause Mortality Files compiled from US death certificates from 1979 through 1997. Using these 2 analyses, we examined median survival time or median age at death, survival beyond 1 year of age, and factors associated with longer survival.

Results. Using Metropolitan Atlanta Congenital Defects Program, we identified 70 liveborn infants with trisomy 13 and 114 liveborn infants with trisomy 18. Median survival time was 7 days (95% confidence interval [CI]: 3–15) for people with trisomy 13 and 14.5 days (95% CI: 8–28) for people with trisomy 18. For each condition, 91% of infants died within the first year. Neither race nor gender affected survival for trisomy 13, but for trisomy 18, girls and infants of races other than white seemed to survive longer. The presence of a heart defect did not seem to affect survival for either condition. Using MCMF, we identified 5515 people with trisomy 13 and 8750 people with trisomy 18 listed on their death certificates. Median ages at death for people with trisomy 13 and trisomy 18 both were 10 days; 5.6% of people with trisomy 13 and 5.6% of people with trisomy 18 died at age 1 year or greater. Race and gender seemed to affect survival in both conditions, with girls and blacks showing higher median ages at death.

Conclusions. Although survival is greatly affected by trisomy 13 and trisomy 18, 5% to 10% of people with these conditions survive beyond the first year of life. These population-based data are useful to clinicians who care for patients with these trisomies or counsel families with infants or fetuses who have a diagnosis of trisomy 13 or 18.

Key Words: trisomy 13 • trisomy 18 • survival • mortality

Abbreviations: MACDP, Metropolitan Atlanta Congenital Defects Program • MCMF, Multiple-Cause Mortality Files • ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification • NDI, National Death Index • CI, confidence interval • ICD-9, International Classification of Diseases, Ninth Revision

Received for publication Apr 30, 2002; Accepted Sep 4, 2002.




This article has been cited by other articles:


Home page
 Hum ReprodHome page
K. O. Kagan, D. Wright, C. Valencia, N. Maiz, and K. H. Nicolaides
Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free {beta}-hCG and pregnancy-associated plasma protein-A
Hum. Reprod., September 1, 2008; 23(9): 1968 - 1975.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
M. P. McGraw and J. M. Perlman
Attitudes of Neonatologists Toward Delivery Room Management of Confirmed Trisomy 18: Potential Factors Influencing a Changing Dynamic
Pediatrics, June 1, 2008; 121(6): 1106 - 1110.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
R H Scott, C A Stiller, L Walker, and N Rahman
Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour
J. Med. Genet., September 1, 2006; 43(9): 705 - 715.
[Abstract] [Full Text] [PDF]

Home page
 J Ultrasound MedHome page
J. R. Wax, A. Cartin, M. G. Pinette, and J. Blackstone
Are Intracardiac Echogenic Foci Markers of Congenital Heart Disease in the Fetus With Chromosomal Abnormalities?
J. Ultrasound Med., July 1, 2004; 23(7): 895 - 898.
[Abstract] [Full Text] [PDF]